Clinical trial
OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell…
NCT00036647 · OSI Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00036647 |
|---|---|
| Title | OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer |
| Official title | A Randomized Placebo Controlled Study of OSI-774 (Erlotinib HCl, Tarceva[TM]) in Patients With Incurable Stage IIIB/IV Non-small Cell Lung Cancer Who Have Failed Standard Therapy for Advanced or Metastatic Disease |
| Lead sponsor | OSI Pharmaceuticals, Industry |
| Collaborators | Canadian Cancer Trials Group |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-small-cell Lung |
| Intervention type | Drug |
| Interventions | Tarceva (erlotinib HCl, OSI-774 ) |
| Enrollment | 731 |
| Start date | Nov 1, 2001 |
| Primary completion | Jan 30, 2004 |
| Completion | Jan 30, 2004 |
| First posted | May 14, 2002 |
| Last update posted | Jan 10, 2018 |
| Countries | Argentina, Australia, Brazil, Canada, Chile, China, Germany, Greece, Israel, Mexico, New Zealand, Romania and 5 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: